Insmed Inc

IM8N

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,664

Stocks News & Analysis

stocks

10 US stocks with the largest fair value estimate increases during Q4 earnings

Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks

Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm

We think Berkshire Hathaway stock is fairly valued.
stocks

Magellan Financial Group: A dilutive acquisition of Barrenjoey

Our view of the proposed merger.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,297.20103.50-1.10%
CAC 408,103.84290.48-3.46%
DAX 4023,790.65847.35-3.44%
Dow JONES (US)48,384.77520.01-1.06%
FTSE 10010,484.13295.98-2.75%
HKSE25,768.08291.77-1.12%
NASDAQ22,452.24296.62-1.30%
Nikkei 22556,279.051,778.19-3.06%
NZX 50 Index13,620.21102.76-0.75%
S&P 5006,800.6580.97-1.18%
S&P/ASX 2009,077.3090.80-0.99%
SSE Composite Index4,122.6859.92-1.43%

Market Movers